These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 15620874)

  • 1. Crystal forms of tolbutamide from acetonitrile and 1-octanol: effect of solvent, humidity and compression pressure.
    Chakravarty P; Alexander KS; Riga AT; Chatterjee K
    Int J Pharm; 2005 Jan; 288(2):335-48. PubMed ID: 15620874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reevaluation of solubility of tolbutamide and polymorphic transformation from Form I to unknown crystal form.
    Hasegawa G; Komasaka T; Bando R; Yoshihashi Y; Yonemochi E; Fujii K; Uekusa H; Terada K
    Int J Pharm; 2009 Mar; 369(1-2):12-8. PubMed ID: 19026732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of physical mixtures and directly compressed tablets of sulfamerazine polymorphs: implications on in vitro release characteristics.
    Roy S; Alexander KS; Riga AT; Chatterjee K
    J Pharm Sci; 2003 Apr; 92(4):747-59. PubMed ID: 12661061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of tolbutamide polymorphs (Burger's forms II and IV) and polymorphic transition behavior.
    Kimura K; Hirayama F; Uekama K
    J Pharm Sci; 1999 Apr; 88(4):385-91. PubMed ID: 10187747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crystal growth formation in melt extrudates.
    Bruce C; Fegely KA; Rajabi-Siahboomi AR; McGinity JW
    Int J Pharm; 2007 Aug; 341(1-2):162-72. PubMed ID: 17524578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization and compaction behaviour of nimesulide crystal forms.
    Di Martino P; Censi R; Barthélémy C; Gobetto R; Joiris E; Masic A; Odou P; Martelli S
    Int J Pharm; 2007 Sep; 342(1-2):137-44. PubMed ID: 17583450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recrystallization of fluconazole using the supercritical antisolvent (SAS) process.
    Park HJ; Kim MS; Lee S; Kim JS; Woo JS; Park JS; Hwang SJ
    Int J Pharm; 2007 Jan; 328(2):152-60. PubMed ID: 16959448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of solvents and crystallization conditions on the polymorphic behaviors and dissolution rates of valsartan.
    Tran TT; Tran PH; Park JB; Lee BJ
    Arch Pharm Res; 2012 Jul; 35(7):1223-30. PubMed ID: 22864745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The solid-state characterization of fusidic acid.
    Gilchrist SE; Letchford K; Burt HM
    Int J Pharm; 2012 Jan; 422(1-2):245-53. PubMed ID: 22100514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solid molecular dispersions of poorly water-soluble drugs in poly(2-hydroxyethyl methacrylate) hydrogels.
    Zahedi P; Lee PI
    Eur J Pharm Biopharm; 2007 Mar; 65(3):320-8. PubMed ID: 17182231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphic properties and dissolution profile of efavirenz due to solvents recrystallization.
    Wardhana YW; Soewandhi SN; Wikarsa S; Suendo V
    Pak J Pharm Sci; 2019 May; 32(3):981-986. PubMed ID: 31278710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crystalline polymorphism and molecular structure of sodium pravastatin.
    Martín-Islan AP; Cruzado MC; Asensio R; Sainz-Díaz CI
    J Phys Chem B; 2006 Dec; 110(51):26148-59. PubMed ID: 17181270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response surface analysis of solution-mediated polymorphic transformation of buspirone hydrochloride.
    Sheikhzadeh M; Murad S; Rohani S
    J Pharm Biomed Anal; 2007 Oct; 45(2):227-36. PubMed ID: 17658715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thermodynamic Stability Analysis of Tolbutamide Polymorphs and Solubility in Organic Solvents.
    Svärd M; Valavi M; Khamar D; Kuhs M; Rasmuson ÅC
    J Pharm Sci; 2016 Jun; 105(6):1901-1906. PubMed ID: 27238487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crystal modification of dipyridamole using different solvents and crystallization conditions.
    Adhiyaman R; Basu SK
    Int J Pharm; 2006 Sep; 321(1-2):27-34. PubMed ID: 16842943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of solvatomorphs of methotrexate using thermoanalytical and other techniques.
    Chadha R; Arora P; Kaur R; Saini A; Singla ML; Jain DS
    Acta Pharm; 2009 Sep; 59(3):245-57. PubMed ID: 19819822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conformational polymorphism of tolbutamide: A structural, spectroscopic, and thermodynamic characterization of Burger's forms I-IV.
    Thirunahari S; Aitipamula S; Chow PS; Tan RB
    J Pharm Sci; 2010 Jul; 99(7):2975-90. PubMed ID: 20091821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-solvent polymorph screen of carbamazepine.
    Getsoian A; Lodaya RM; Blackburn AC
    Int J Pharm; 2008 Feb; 348(1-2):3-9. PubMed ID: 17945448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diclofenac nanosuspensions: influence of preparation procedure and crystal form on drug dissolution behaviour.
    Lai F; Sinico C; Ennas G; Marongiu F; Marongiu G; Fadda AM
    Int J Pharm; 2009 May; 373(1-2):124-32. PubMed ID: 19429297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crystal morphologies and polymorphs in tolbutamide microcrystalline powder.
    Li Destri G; Marrazzo A; Rescifina A; Punzo F
    J Pharm Sci; 2013 Jan; 102(1):73-83. PubMed ID: 23042550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.